Incorporated in 1974, Temasek is a global investment company headquartered in Singapore. Supported by a network of international offices, Temasek owns a S$308 billion (US$235b) portfolio as at 31 March 2018, with significant exposure to Singapore and the rest of Asia.
Temasek's investment activities are guided by four investment themes and the long-term trends they represent: Transforming Economies; Growing Middle Income Populations; Deepening Comparative Advantages; and Emerging Champions.
For more information on Temasek, please visit www.temasek.com.sg
About Lilly Asia Ventures
Lilly Asia Ventures ("LAV") is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto, California. Its vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.
For more information on LAV, please visit www.lillyasiaventures.com
Orbimed has been investing globally for over 20 years across the healthcare industry: from early-stage private companies to large multinational corporations. Our team of over 80 distinguished scientific, medical, investment and other professionals manages over $13 billion across public and private company investments worldwide.
For more information on Orbimed, please visit www.orbimed.com
About Kington Capital
Established in 2016, Kington Capital is the first municipal-level privately-owned equity investment platform approved and supported by Suzhou government. Kington Capital, together with its subsidiaries, engages in business including PE and VC investment, FOF and family wealth management. In terms of PE and VC investment, Kington Capital primarily focuses on healthcare, next generation information technology and branded consumer goods/services.